Parkinson's Disease Patients Research Articles

Mutated LRRK2 induces a reactive phenotype and alters migration in human iPSC-derived pericyte-like cells

Abstract Background Pericytes play a crucial role in controlling inflammation and vascular functions in the central nervous system, which are disrupted in Parkinson’s disease (PD). Still, there is a lack of studies on the impact of pericytes on neurodegenerative diseases, and their involvement in the pathology of PD is unclear. Our objective was to investigate the molecular and functional differences between healthy pericytes and pericytes with the LRRK2 G2019S mutation, which is one of the most common mutations associated with PD. Methods Our study employed pericyte-like cells obtained from induced pluripotent stem cells produced from PD patients with the LRRK2 G2019S mutation as well as from healthy individuals. We examined the gene expression profiles of the cells and analyzed how the alterations reflect on their functionality. Results We have shown differences in the expression of genes related to inflammation and angiogenesis. Furthermore, we observe modified migration speed in PD pericyte-like cells as well as enhanced secretion of inflammatory mediators, such as soluble VCAM-1 and MCP-1, in these pericyte-like cells following exposure to proinflammatory stimuli. Conclusions In summary, our findings support the notion that pericytes play a role in the inflammatory and vascular changes observed in PD. Further investigation of pericytes could provide valuable insight into understanding the pathogenesis of PD.

From central to peripheral: A new perspective on bladder dysfunction in Parkinson disease

As opposed to classical overactive (OAB) symptoms, Parkinson disease (PD) patients often exhibit detrusor hyperreflexia and impaired contractility or underactive bladder. OAB would be more related to central nervous system dysfunction, but nerve damage in peripheral ganglia (eg, pelvic ganglia in the bladder wall) may play a mechanism of dysfunction manifesting as underactive bladder in PD. We propose a novel hypothesis regarding neurogenic urologic dysfunction in PD, suggesting a potential involvement of peripheral nervous system dysfunction in addition to central nervous system dysfunction. This hypothesis emphasizes the significance of investigating peripheral neuron damage in the urinary bladder. We hereby review the relevant neurogenic bladder dysfunction associated with PD, compare and contrast OAB and underactive bladder manifestations and dysfunction, and discuss novel considerations toward this disease with great unmet needs.

Efficacy and safety of safinamide in Parkinson's disease patients with motor fluctuations without levodopa dosage escalation over 18 weeks: KEEP study.

This multicentre, prospective, single-arm study evaluated safinamide as add-on therapy to levodopa in Korean patients with Parkinson's disease (PD) with motor fluctuations with≥1.5 h of "off" time daily, who took levodopa≥3 times/day (n = 199). Baseline levodopa and dopamine agonist doses were maintained without escalation during the 18-week treatment period. Participants received safinamide 50 mg/day for 2 weeks and 100 mg/day thereafter. PD diaries and questionnaires (Parkinson's Disease Questionnaire, PDQ-39; Movement Disorder Society-Sponsored Revision of the Unified Parkinson's Disease Rating Scale, MDS-UPDRS part 3 and part 4; King's Parkinson's Disease Pain Scale, KPPS; Mini-Mental State Examination, MMSE) were assessed at baseline and at week 18. Treatment-emergent adverse events (TEAEs) were recorded. Mean disease duration was 6.6 years, and mean levodopa equivalent daily dose was 721.1 mg/day. At week 18, significant improvements from baseline were seen for the co-primary endpoints, mean daily "off" time (-1.3±2.4 h, p<0.001) and quality of life (QoL) based on PDQ-39 summary index (-2.7±10.3, p<0.001), Moreover, significant improvements were seen in motor symptoms and motor complications (MDS-UPDRS part 3 and 4), daily "on" time without dyskinesia (all p<0.001) and pain (KPPS; p = 0.013). TEAEs occurred in 40.2% of patients, with most being mild in severity. In conclusion, safinamide at a dosage of 100 mg/day significantly improved motor symptoms, QoL, and pain, and demonstrated a favourable safety profile without levodopa dosage escalation during the 18-week treatment period in Korean patients with PD.Trial registration number and date: NCT05312632, First Posted: April 5, 2022.

Discriminating Parkinson's disease patients from healthy controls using nasal respiratory airflow.

Breathing patterns may inform on health. We note that the sites of earliest brain damage in Parkinson's disease (PD) house the neural pace-makers of respiration. We therefore hypothesized that ongoing long-term temporal dynamics of respiration may be altered in PD. We applied a wearable device that precisely logs nasal airflow over time in 28 PD patients (mostly H&Y stage-II) and 33 matched healthy controls. Each participant wore the device for 24 h of otherwise routine daily living. We observe significantly altered temporal patterns of nasal airflow in PD, where inhalations are longer and less variable than in matched controls (mean PD = -1.22 ± 1.9 (combined respiratory features score), Control = 1.04 ± 2.16, Wilcoxon rank-sum test, z = -4.1, effect size Cliff's δ = -0.61, 95% confidence interval = -0.79 - (-0.34), P = 4.3 × 10-5). The extent of alteration is such that using only 30 min of recording we detect PD at 87% accuracy (AUC = 0.85, 79% sensitivity (22 of 28), 94% specificity (31 of 33), z = 5.7, p = 3.5 × 10-9), and also predict disease severity (correlation with UPDRS-Total score: r = 0.49; P = 0.008). We conclude that breathing patterns are altered by H&Y stage-II in the disease cascade, and our methods may be further refined in the future to provide an indication with diagnostic and prognostic value.

Anti-obesity effect of irreversible MAO-B inhibitors in patients with Parkinson's disease.

We read with great interest the report on the new anti-obesity potential in mice models of reversible monoamine oxidase B inhibitors by Moonsun et al., as opposed to the lack of such effects observed with irreversible MAO-B inhibitors (iMAO-Bi). Our research aimed to explore the potential anti-obesity effects of iMAO-Bi in patients with Parkinson's disease (PD). This retrospective study included 37 PD in-patients from 2018 to 2023. Patients who took iMAO-Bi were assigned to the iMAO-Bi group, and those who never took iMAO-Bi were assigned to the control. The major outcomes were changes in body weight and body mass index (BMI) during follow-up. A subgroup analysis was conducted to compare the anti-obesity effect between the short-term and long-term administrations of the iMAO-Bi group. The results showed a slight yet insignificant trend of bodyweight loss among the iMAO-Bi group of PD patients. Subgroup analysis showed that short-term treatment of iMAO-Bi (less than six months) led to reductions in BMI and body weight, while the long-term treatment of iMAO-Bi displayed a slight increase in BMI and body weight. The results suggested that short-term administration of iMAO-Bi may have potential weight-loss effects. Further studies with larger sample sizes are needed to evaluate the weight-loss effect of iMAO-Bi.

Increased Survival in Contemporary Parkinson's Disease - a 47 year autopsy study.

Parkinson's disease (PD) is the second most common neurodegenerative disorder. The main clinical features are: bradykinesia, rigidity and resting tremor. Other neurodegenerative disorders such as progressive supranuclear palsy and multiple system atrophy share some of these clinical manifestations. All those disorders are collectively known as parkinsonism or Parkinson syndrome (PS). Definite diagnosis of PD requires brain autopsy. There is no known cure for PD. Since its discovery in the 1960s, levodopa (LD) has remained the best and most widely used medication in PD. The impact of that is important to understanding the neuroepidemiology of PD. The incidence of PD rises with advancing age. In the last six decades, life expectancy in the general population has increased resulting in a larger pool of at-risk persons. Onset age of PD is the most reliable indicator of PD survival, as older onset cases have shorter survival. We report on survival in autopsy-confirmed PD cases with onset-age <70 years treated with LD and compare that with similar onset age cases of PD before the discovery of LD. The Saskatchewan Movement Disorders Program (SMDP) has operated uninterrupted since 1968. Long follow-up and autopsy studies are a special interest of the SMDP. All PS cases followed by the SMPD during 47 years (1968-2015) that came to autopsy were considered. Those with autopsy-confirmed PD and onset <70 years were included and were compared with pre-LD cases of similar age of onset. 392 PS cases were seen in our clinic between 1968-2015 and had brain pathology studies. 314 (80%) of those had PD. 128 (41%) of the PD cases had onset <70 years and were included in this study. Their median survival was 18 years. Prior to widespread use of LD, nearly all PD cases had onset <70 years and mean survival was 9.4 years. Longer survival in our study is attributed primarily to modern treatment. Increased survival has resulted in a larger number of older, chronically treated, higher comorbidity, and complicated PD patients. These changes present new challenges. It requires a larger and increasingly diverse workforce for patient care and research.

Dysregulated Coagulation in Parkinson’s Disease

Parkinson’s disease (PD), a prevalent neurodegenerative disorder characterized by dopaminergic neuron degeneration and α-synuclein accumulation, has been increasingly associated with coagulation dysfunction. This review synthesizes emerging evidence linking dysregulated coagulation to PD pathophysiology. We examine the alterations in coagulation parameters, including elevated fibrinogen levels, impaired fibrinolysis, and platelet dysfunction, which collectively contribute to a hypercoagulable state in PD patients. Epidemiological studies have revealed a higher incidence of thrombotic events, such as deep vein thrombosis (DVT) and stroke, among PD patients, suggesting significant comorbidity between PD and coagulation disorders. This review explores the potential pathophysiological mechanisms underlying this association, focusing on the roles of inflammation and oxidative stress. Additionally, we discuss the limitations of current research and propose future directions. This comprehensive analysis underscores the importance of understanding the coagulation–neurodegeneration axis in PD, which may lead to novel diagnostic and therapeutic strategies for this debilitating condition.

Parkinson's disease and posture: evaluation with biometrical holistic of human body device: a pilot study

BackgroundPatients with Parkinson's disease (PD) commonly develop severe spinal deformity. The etiology of Parkinson's spinal deformity is not completely understood and in most cases is likely due to multiple factors. These include dystonia and focal myopathy. Clinical, neurophysiological, and radiological data must be considered to monitor the pathology and the effects of rehabilitation. The aim of this pilot study is to evaluate spine alignment with a surface topography analysis of Parkinson's patients with Biometrical Holistic of Human Body (BHOHB®) and to compare results with their x-rays spine standard as already done for adolescent scoliosis.Methods32 adult patients affected by Parkinson disease, have been evaluated with BHOHB ®. The correspondence of the Cobb angles were evaluated using the BHOHB device and with standard spinal x-rays.ResultsA total of 32 patients were enrolled. The mean age was 67.45 years. In this pilot study the measurement of the correlations between the radiological and BHOHB® Cobb angles of the patients were excellent.ConclusionThis preliminary result supports the use of BHOHB® as a device useful to monitor and measure posture in Parkinson's. This needs to be evaluated on a larger sample and over time. Keywords: Parkinson's disease, scoliosis, postural imbalance, neurophysiology.

Online training program maintains motor functions and quality of life in patients with Parkinson's disease

ObjectiveSeveral systematic reviews have shown that physical exercise positively affects motor function (MF) and quality of life (QoL) in patients with Parkinson's disease (PD). After the coronavirus disease (COVID-19) pandemic, numerous studies were conducted to reveal the effects of telerehabilitation for patients with PD. However, only a few empirical results of online programs for PD patients have been reported. Therefore, this study aimed to determine the effects of an online physical and cognitive training program on MF and QoL in patients with PD.MethodsWe evaluated the impact of our online program on the QoL and MF of patients with PD by comparing data at baseline and after six months of intervention. For the QoL assessment, we used the Schwab and England Activities of Daily Living scale and Parkinson's Disease Questionnaire (PDQ-39), whereas, for MF, we measured movement status using the modified 20-m walk test and timed up-and-go (TUG) test.ResultsWe enrolled 20 patients for QoL and 19 for MF in this study. For PDQ-39, social support (p = 0.046, δ = 0.320) and cognitions (p = 0.028, δ = 0.268) significantly improved. Additionally, cadence (p = 0.032, g = −0.377) in the modified 20-m walk and exam duration (p = 0.003, δ = 0.296) and forward gait (p = 0.003, δ = 0.341) in the TUG test showed significant differences before and after the intervention.ConclusionOur results suggest that online physical and cognitive training programs positively affect MF and QoL in individuals with PD.

Abstract 4138617: Temporal and Regional Trends in Cardiovascular Mortality Associated with Parkinson's Disease from 1999 to 2020: A Retrospective Study in the United States

Introduction: Parkinson’s disease (PD) is a common neurodegenerative disorder, and existing evidence links it to cardiovascular (CVD) mortality. Research Question: Is the CVD-related mortality higher in PD patients compared to that in the general population? Goals: We aim to identify CVD-related mortality trends in patients with PD in the US stratified by age, sex, race, and region, and compare them to CVD-related mortality trends in the general population. Methods: Death certificates from the CDC-WONDER database were examined for adults aged ≥65 years. Crude rates (CR) and age-adjusted mortality rates (AAMRs) per 100,000 persons were calculated, and change in AAMR was estimated via annual percent change (APC) and the average annual percent change (AAPC) using Joinpoint regression. Results: From 1999 to 2020, a total of 138,151 CVD-related deaths occurred in individuals with PD. The AAMRs decreased moderately till 2002 (APC: -3.25), then sharply till 2014 (APC: -5.43), but increased thereafter till 2020 (APC: 1.77). Males had higher AAMR than females, and the AAPC for CVD-related deaths in PD differed significantly from those in the general population. NH Whites displayed the highest AAMR (16.14) while NH Blacks or African Americans displayed the lowest (9.65). Hispanics or Latinos showed an AAMR of 11.22, followed by NH Asians or Pacific Islanders (10.24) and NH American Indians or Alaska Natives (9.70). AAMRs also varied substantially by region (West: 16.64; Midwest: 16.40; Northeast: 15.59; South: 13.12). States with the highest AAMRs were Nebraska, California, and Oklahoma. Rural regions exhibited a higher AAMR (16.34) than Urban regions (14.88). The AAPC for CVD-related deaths in PD differed significantly from those in the West and in urban regions. Most deaths occurred at nursing homes or long-term care (43.85%). The adults aged ≥85 years exhibited an alarmingly high CR (53.04), and the AAPC differed significantly from the general population due to CVD. Conclusions: We observed overall decreasing trends in CVD-related deaths in adults with PD from 1999 to 2014, which increased thereafter till 2020. Highest mortality was exhibited by males and NH Whites, residents of the West and the Midwest, and adults ≥85 years.

Efficacy of acupuncture in ameliorating anxiety in Parkinson's disease: a systematic review and meta-analysis with trial sequential analysis

BackgroundAlthough numerous studies have explored acupuncture for alleviating Parkinson's disease (PD) symptoms, specific methods focusing on reducing anxiety in these patients are lacking. Preliminary research indicates that acupuncture may improve anxiety in patients with Parkinson's; however, high-quality evidence is lacking. Therefore, we conducted a meta-analysis and trial sequential analysis (TSA) to assess the efficacy of acupuncture in managing anxiety symptoms in PD.MethodsWe systematically searched eight databases for randomized controlled trials (RCTs) evaluating the efficacy of acupuncture for the treatment of anxiety in patients with PD. Primary outcomes were measured using the Hamilton Anxiety Scale (HAMA) and the Self-Rating Anxiety Scale (SAS). Secondary outcomes included the Parkinson's Disease Questionnaire-39 (PDQ-39) and the Unified Parkinson's Disease Rating Scale (UPDRS). Risk of bias was assessed using the Cochrane RoB 2.0 tool, and certainty of evidence was assessed using the GRADE system. The Trial Sequential Analysis (TSA) was used to assess the sufficiency of the evidence.ResultsOur meta-analysis included 14 studies. The Manual acupuncture (MA) + routine drug treatment (RDT) group improved more than the RDT alone group. MA was more effective than sham acupuncture. MA+ traditional Chinese medicine (TCM) was also more effective than TCM. Auricular therapy (AT) was not as effective as control therapy (CT). The Electroacupuncture (EA) + routine drug treatment (RDT) group was not as effective as RDT. PDQ-39 and UPDRS subgroup analysis showed that the acupuncture group had better clinical efficacy than CT. The GRADE assessment rated the overall certainty of evidence for anxiety outcomes as low, PDQ-39 as very low and UPDRS as low. TSA results indicate insufficient evidence; further high-quality RCTs are needed to substantiate these findings.ConclusionOur analysis suggests that MA combined with RDT may help ameliorate anxiety in PD patients, although the evidence is weak due to low quality RCTs. EA and AT showed no significant effects, highlighting the need for more rigorous studies with better controls and longer follow-up. The potential of acupuncture for PD-related anxiety should be considered with caution until stronger evidence becomes available.Systematic review registrationhttps://www.crd.york.ac.uk/PROSPERO/.

ASC specks as a single-molecule fluid biomarker of inflammation in neurodegenerative diseases.

Immunotherapeutic strategies for Alzheimer's and Parkinson's disease would be facilitated by better measures of inflammation. Here we established an ultra-sensitive single-molecule pull-down immunoassay combined with direct stochastic optical reconstruction microscopy (dSTORM) to measure the number, size and shape of individual extracellular inflammasome ASC specks. We assayed human post-mortem brain, serum and cerebrospinal fluid of patients with Parkinson's and Alzheimer's as well as healthy elderly. The number of ASC specks increased and showed altered morphology in the blood of early-stage Parkinson's and Alzheimer's patients compared to controls, mimicking those found in the brain and cerebrospinal fluid. In serum samples we also measured the number of Aβ, p-tau and α-syn aggregates and formed a composite biomarker of (ASC + p-tau)/Aβ and (ASC + α-syn)/Aβ ratios that distinguished age-matched healthy controls from patients with early-stage Alzheimer's with AUC of 92% and early-stage Parkinson's with AUC of 97%. Our findings confirm ASC specks as a fluid candidate biomarker of inflammation for neurodegenerative diseases with blood being the main focus for further development as convenient sample for diagnostics and clinical trials.

An Automated Diagnosis of Parkinson's Disease from MRI Scans Based on Enhanced Residual Dense Network with Attention Mechanism.

The increasing prevalence of neurodegenerative diseases has recently heightened interest in research on early diagnosis of these diseases. Parkinson's disease (PD), among the most prominent of these conditions, is a neurological disorder causing the loss of nerve cells and significantly affecting movement control. Detection of PD in early stages is of critical importance to prevent the progression of the disease and improve treatment processes. The aim of the current study is to develop a deep learning model that can perform accurate classification for early diagnosis of PD from MRI images. In this study, a densely connected feature fusion network with residual learning is designed to diagnose PD patients. The designed network consists of a serial dense block with skip connections and efficient attention mechanisms. In this architecture, squeeze-excitation (SE) blocks with ResNeXt (SE-ResNeXt block) modules are utilized to extract distinctive and high-level features. In the experiments, a publicly available T2-weighted MRI dataset is used, and an offline augmentation process is applied to limited data to increase the generalization ability and classification performance. The proposed method is evaluated and compared with current state-of-the-art deep learning methods. The obtained results show that the proposed model gives higher classification performance with an overall accuracy of 94.44%, precision of 91.67%, sensitivity of 91.67%, specificity of 95.83%, F1-score of 91.67%, and Matthew's correlation coefficient of 87.50% for the PD and healthy control subjects.

Impact of Harmonization on MRI Radiomics Feature Variability Across Preprocessing Methods for Parkinson's Disease Motor Subtype Classification.

This study aimed to assess the reproducibility of MRI-derived radiomic features across multiple preprocessing methods for classifying Parkinson's disease (PD) motor subtypes and to evaluate the impact of ComBat harmonization on feature stability and machine learning performance. T1-weighted MRI scans from 140 PD patients (70 tremor-dominant and 70 postural instability gait difficulty) and 70 healthy controls were obtained from the Parkinson's Progression Markers Initiative (PPMI) database, acquired using different scanner models. Radiomic features were extracted from 16 brain regions using various preprocessing pipelines. ComBat harmonization was applied using a combined batch variable incorporating both scanner models and preprocessing methods. Intraclass correlation coefficients (ICC) and Kruskal-Wallis tests assessed feature reproducibility before and after harmonization. Feature selection was performed using Linear Support Vector Classifier with L1 regularization. Support vector machine classifiers were used for PD subtype classification. ComBat harmonization significantly improved feature reproducibility across all feature groups. The percentage of features showing excellent robustness (ICC ≥ 0.90) increased from 40.2 to 56.3% after harmonization. First-order statistic features showed the highest robustness, with 71.11% demonstrating excellent ICC after harmonization. The proportion of features significantly affected by preprocessing methods was reduced following harmonization. Classification accuracy improved dramatically, from a range of 34-75% before harmonization to 89-96% after harmonization across all preprocessing methods. AUC values similarly increased from 0.28-0.87 to 0.95-0.99 after harmonization. ComBat harmonization significantly enhanced the reproducibility of radiomic features across preprocessing methods and improved PD motor subtype classification performance. This study highlights the importance of harmonization in radiomics research for PD and suggests potential clinical applications in personalized treatment planning.

Novelty Seeking in Parkinson’s Disease: A Candidate Biomarker for Cognitive Changes

Background: Parkinson’s disease (PD) is a common neurodegenerative disorder characterized by motor impairments, cognitive decline, and affective changes. Beyond the well-described motor symptoms, neuropsychiatric symptoms play a crucial role in PD disability burden. Novelty seeking, a trait extensively studied within various models of personality, may influence the manifestation of these non-motor symptoms. Methods: A narrative review of articles determined relevant by the author(s) was undertaken. Results: The literature indicates that PD patients typically exhibit low novelty seeking initially. However, dopaminergic therapies can increase novelty-seeking behaviors, sometimes leading to impulse control disorders (ICD). Studies using the Temperament and Character Inventory (TCI) suggest a complex interplay between disease state, medication, and baseline personality, which is not fully elucidated. High novelty seeking scores predict a higher risk of ICDs, yet they also correlate with a more benign clinical phenotype and improved quality of life post-DBS surgery. Conclusions: Novelty seeking is a significant trait in PD, influencing non-motor symptoms and treatment responses. Understanding its neurobiological basis and clinical implications could lead to better diagnostic and therapeutic strategies through the use of objective, practical tools for disease monitoring, individualized therapy, and pharmacological development.

Oral Transport, Penetration, and Aspiration in PD: Insights from a RCT on STN + SNr Stimulation.

Dysphagia is frequent and detrimental in advanced Parkinson's disease (PD) and does not respond to standard treatments. Experimental models suggested that pathological overactivity of the substantia nigra pars reticulata (SNr) may hinder oral contributions to swallowing. Here, we hypothesized that the combined stimulation of subthalamic nucleus (STN) and SNr improves measures of dysphagia after eight weeks of active treatment. We enrolled 20 PD patients with dysphagia and deep brain stimulation (DBS). Patients were assessed in 'medication on' and 'STN' stimulation at baseline (V1) and then were randomized 1:1 to 'STN' or 'STN + SNr' stimulation. In addition, patients of both groups received swallowing therapy as a standard of care. The primary endpoint was the change in Penetration-Aspiration Scale (PAS) at eight-week follow-up (V2) with respect to the baseline (V1) under the hypothesis, that 'STN + SNr' was superior to 'STN'. We obtained further secondary endpoints on oral preparation, transport, pharyngeal phase, penetration, and aspiration. PAS change from V1 to V2 was not significantly different between groups (p = 0.221). When considering all patients for secondary analyses, we found that the entire study cohort showed better PAS scores at V2 compared to V1 irrespective from DBS treatment allocation (p = 0.0156). Both STN and STN + SNr treatments were safe. 'STN + SNr' stimulation was not superior compared to standard 'STN' stimulation both on PAS and the secondary endpoints. We found that the entire study cohort improved dysphagia after eight weeks, which presumably mirrors the effect of continued swallowing therapy and the increased patient attention on swallowing.

EHospitals and Parkinson’s disease care: audit insights from an EPIC-integrated Hospital

Abstract Introduction Parkinson’s disease (PD) is a neurodegenerative condition that affects approximately 145,000 individuals in the UK. PD symptoms are managed primarily through medications such as levodopa and dopamine agonists. Delays or omissions in administering these medications is the primary reason for increased length of stay in up to 73% of emergency admissions.1 This audit investigated the management of PD medications at Cambridge University Hospitals to identify areas for improvement in clinical practice. Aim This audit aimed to evaluate the pharmacological management of PD patients admitted to Cambridge University Hospitals NHS Trust. Specifically, it sought to assess the accuracy of drug histories, the quality of medication administration, and adherence to standards set by Parkinson’s UK ‘Get it on Time’ campaign and NICE.2,3 Methods A cross-sectional audit was conducted, reviewing the records of PD patients admitted over a three-month period. The sample included patients with a confirmed diagnosis of idiopathic PD who were prescribed at least one PD medication. Data were collected retrospectively from the electronic patient records, focusing on ten performance standards. Ethical approval was not required as the study involved a retrospective review of existing clinical records. Results The audit included 63 admissions, predominantly male (65%) with a mean age of 78.5 years. A significant portion of patients (81%) had their drug histories completed by a doctor after clerking, and 90% had orders for their regular treatment generated immediately post-clerking. Pharmacy staff completed drug histories within 24 hours for 81% of patients, though discrepancies between medical and pharmacy histories were noted in 70% of cases. Medication reconciliation within 24 hours was achieved for 83% of patients, yet only 29% received their PD medications on time for every dose. Additionally, 76% did not miss a dose or had a valid reason recorded for missed doses. 83% had PD listed in their electronic problem list after clerking. Alarmingly, just 5% were assessed for Self-Administration of Medicines (SAM), and 76% were assessed by a PD specialist during their stay. Discussion and conclusion The audit revealed substantial gaps in PD medication management, particularly regarding discrepancies between medical and pharmacy drug histories and delays in medication administration. The low rate of SAM assessments and inconsistent PD specialist consultations were also significant concerns. These findings highlight the need for improved documentation practices, such as standardized templates within the EPIC system, and increased pharmacy involvement during early stages of admission. Appropriate staffing levels and better interdisciplinary coordination are essential. The audit identified critical areas for improvement, emphasizing the need for better documentation, timely administration, and enhanced interdisciplinary coordination. Future audits should aim to randomize patient selection over a longer period to minimize bias and provide a more comprehensive assessment of medication management practices. The audit was limited by its retrospective design and the specific three-month timeframe, which may not fully represent broader trends. The exclusion of admissions shorter than 24 hours and the focus on a single hospital trust also limit the generalizability of the findings. Future studies should consider a larger, more randomized sample to validate and expand upon these results.

State identification of Parkinson's disease based on transfer learning.

The local field potential (LFP) signals are a vital signal for studying the mechanisms of deep brain stimulation (DBS) and constructing adaptive DBS containing information related to the motor symptoms of Parkinson's disease (PD). A Parkinson's disease state identification algorithm based on the feature extraction strategy of transfer learning was proposed. The algorithm uses continuous wavelet transform (CWT) to convert one-dimensional LFP signals into two-dimensional gray-scalogram images and color images respectively, and designs a Bayesian optimized random forest (RF) classifier to replace the three fully connected layers for the classification task in the VGG16 model, to realize automatic identification of the pathological state of PD patients. It was found that consistently superior performance of gray-scalogram images over color images. The proposed algorithm achieved an accuracy of 97.76%, precision of 99.01%, recall of 96.47%, and F1-score of 97.73%, outperforming feature extractors such as VGG19, InceptionV3, ResNet50, and the lightweight network MobileNet. This algorithm has high accuracy and can distinguish the disease states of PD patients without manual feature extraction, effectively assisting the working of doctors.

Intersection of Sleep Disorders and Parkinson Disease: Unveiling the Bidirectional Relationship.

Patients with Parkinson's Disease (PD) frequently exhibit non-motor symptoms, particularly sleep disturbances. Sleep disorders in PD patients are intricately linked to the pathogenesis and progression of PD itself, exacerbating neurodegenerative processes and worsening patient quality of life. This review underscores the significance of sleep disorders in PD, highlighting their prevalence, impact on disease progression, and the bidirectional relationship between sleep disruption and neurodegeneration. It aims to enhance clinician awareness for better diagnosis and management of sleep-related comorbidities in PD. A comprehensive literature search was conducted in PubMed and Scopus using key terms such as "sleep disorders", "Parkinson's disease", "REM sleep behavior disorder", "restless legs syndrome", "insomnia", "obstructive sleep apnea", "excessive daytime sleepiness", "circadian rhythm disorders", "sleep and neurodegeneration". Sleep disorders are prevalent in PD affecting up to 90% of patients. Conditions such as insomnia, REM sleep behavior disorder, restless legs syndrome, obstructive sleep apnea, excessive daytime sleepiness, and circadian rhythm disorders are commonly reported. These disorders are linked to multifactorial biological mechanisms and are associated with more severe disease phenotypes. Of note, several evidence shows that sleep abnormalities may contribute to neuroinflammation and neurodegeneration, further accelerating the disease course. Sleep disturbances are critical non-motor symptoms in PD. Early diagnosis and tailored management of sleep disorders are essential for improving clinical outcomes and potentially offering neuroprotective benefits.

Transcranial direct current stimulation for Parkinson's disease: systematic review and meta-analysis of motor and cognitive effects.

Transcranial direct current stimulation (tDCS) is a promising noninvasive intervention for Parkinson's disease (PD). However, studies of its motor and cognitive effect have produced mixed results. We conducted a systematic review including 38 studies and meta-analysis of 12 randomized sham-controlled trials with 263 PD patients. No significant differences were found between active and sham tDCS in motor function (UPDRS-III: SMD = -0.14, p = 0.74), gait (SMD = 0.10, p = 0.513), attention and working memory (SMD = 0.24, p = 0.13), executive function (SMD = 0.03, p = 0.854), and memory and learning (SMD: -0.07, p = 0.758). The prediction intervals indicated substantial heterogeneity among studies. Meta-regression showed small positive effects in younger PD patients with milder symptoms. These findings are preliminary but suggest tDCS may benefit some PD patients while being neutral or harmful to others.